PHARNEXT To Present At 4th International Neurotech Investing And Partnering Conference

Published: Sep 29, 2017

PARIS--(BUSINESS WIRE)--Regulatory News:

Pharnext SA (FR00111911287 - ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 4th International Neurotech Investing and Partnering Conference.

The presentation will take place as follows:

  • Date: Wednesday, October 4th, 2017
  • Time: 4:00pm CEST
  • Venue: Wyss Center in Geneva, Switzerland

If you are interested in meeting the Pharnext management team during this event, please send an email to Anne Hennecke at

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit

Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
Financial Communication (France)
Stéphane Ruiz, +33 (0)1 56 88 11 15
Media Relations (Europe)
Caroline Carmagnol
Margaux Pronost
+33 (0)1 44 54 36 64
Media Relations (U.S.)
Marion Janic
+1 212 223 4017

Back to news